<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Leonabio, Inc. — News on 6ix</title>
    <link>https://6ix.com/company/leonabio-inc</link>
    <description>Latest news and press releases for Leonabio, Inc. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 23 Apr 2026 20:05:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/leonabio-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d766cb51cc36e47533b2cf.webp</url>
      <title>Leonabio, Inc.</title>
      <link>https://6ix.com/company/leonabio-inc</link>
    </image>
    <item>
      <title>LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer</title>
      <link>https://6ix.com/company/leonabio-inc/news/leonabio-to-host-virtual-key-opinion-leader-event-highlighting-potential-of-lasofoxifene-in-treatment-resistant-erher2-esr1-mutated-metastatic-breast-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/leonabio-inc/news/leonabio-to-host-virtual-key-opinion-leader-event-highlighting-potential-of-lasofoxifene-in-treatment-resistant-erher2-esr1-mutated-metastatic-breast-cancer</guid>
      <pubDate>Thu, 23 Apr 2026 20:05:00 GMT</pubDate>
      <description>Management to be Joined by Two Clinical Leaders in the Breast Cancer Field Expected to Complete Enrollment in Ongoing ELAINE-3 Phase 3 Registrational Study of Lasofoxifene in Metastatic Breast Cancer in 4Q26 with Data Expected in 2H27 Webinar Event on Wednesday, April 29, 2026, at 12:00 p.m. ET BOTHELL, Wash., April 23, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet</description>
    </item>
    <item>
      <title>Independent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio’s Data</title>
      <link>https://6ix.com/company/leonabio-inc/news/independent-nonclinical-research-on-lasofoxifene-presented-at-american-association-for-cancer-research-annual-meeting-2026-consistent-with-leonabios-data</link>
      <guid isPermaLink="true">https://6ix.com/company/leonabio-inc/news/independent-nonclinical-research-on-lasofoxifene-presented-at-american-association-for-cancer-research-annual-meeting-2026-consistent-with-leonabios-data</guid>
      <pubDate>Tue, 21 Apr 2026 11:00:00 GMT</pubDate>
      <description>Results showed lasofoxifene protected against hormone withdrawal-induced bone loss and maintained a robust anti-tumor response in primary and metastatic animal models of ER+ breast cancerBOTHELL, Wash., April 21, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, attended the American Association for Cancer Research Annual Meeting 2026 (AACR26), where ind</description>
    </item>
    <item>
      <title>LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/leonabio-inc/news/leonabio-reports-full-year-2025-financial-results-and-provides-business-update</link>
      <guid isPermaLink="true">https://6ix.com/company/leonabio-inc/news/leonabio-reports-full-year-2025-financial-results-and-provides-business-update</guid>
      <pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
      <description>Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar</description>
    </item>
    <item>
      <title>LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer</title>
      <link>https://6ix.com/company/leonabio-inc/news/leonabio-appoints-industry-veteran-mark-f-kubik-as-chief-business-officer</link>
      <guid isPermaLink="true">https://6ix.com/company/leonabio-inc/news/leonabio-appoints-industry-veteran-mark-f-kubik-as-chief-business-officer</guid>
      <pubDate>Tue, 03 Feb 2026 05:00:00 GMT</pubDate>
      <description>Brings more than 25 years of biopharma business development and corporate strategy expertise BOTHELL, Wash., Feb. 03, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc.</description>
    </item>
  </channel>
</rss>